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ABSTRACT
Nowadays, the world is facing an increasing emergence of antibiotic resistant bacteria.
Simultaneously, the banning of some existing antibiotics and the lack of development of new
antimicrobials have created an urgent need to find new alternatives against animal infections.
Bacteriophages (phages) are naturally occurring predators of bacteria, ubiquitous in the environ-
ment, with high host specificity and harmless to animals. For these reasons, phages and their
derivatives are being considered valuable antimicrobial alternatives and an opportunity to reduce
the current use of antibiotics in agri-food production, increasing animal productivity and provid-
ing environmental protection. Furthermore, the possibility of combining phage genetic material
with foreign genes encoding peptides of interest has enabled their use as vaccine delivery tools.
In this case, besides bacterial infections, they might be used to prevent viral infections. This
review explores current data regarding advances on the use of phages and phage-encoded pro-
teins, such as endolysins, exolysins and depolymerases, either for therapeutic or prophylactic
applications, in animal husbandry. The use of recombinant phage-derived particles or genetically
modified phages, including phage vaccines, will also be reviewed.
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Introduction
Livestock production frequently involves raising animals
in confined conditions, promoting the easy and fast
spread of infectious diseases. To prevent and treat these
diseases, antibiotics have been a common practice for
decades. Indeed, more than one hundred different anti-
microbials have been used in food-producing animals
(Hao et al., 2014). In addition to their therapeutic use,
some antibiotics modulate the digestive flora and
immune system and thus have been used as growth
promoters to increase animal growth and feed conver-
sion rates. However, this has been leading to antibiotic
overuse, threatening their efficacy due to the emer-
gence and spread of antibiotic resistant bacteria (Page
& Gautier, 2012), and causing a negative environmental
impact. Currently, the amount of antibiotics used in live-
stock is by far the largest portion of all antibiotics used
worldwide, exceeding those used in human medicine
(Mellon et al., 2001), mostly from the same class in both
medical fields (Phillips et al., 2004). In 2010, approxi-
mately 63,151 tons of antimicrobials were used in live-
stock worldwide. By 2030, this consumption is expected
to increase by 67% (Hollis & Ahmed, 2013, Van Boeckel
et al., 2015). Most of these antibiotics are used for non-
therapeutic purposes, as growth promotion and disease
prevention (Mellon et al., 2001). Tetracyclines are the
most commonly used veterinary antibiotics followed by
sulfonamides and macrolides (Kim et al., 2011).
Overall, the continuing increase and emergence of
antimicrobial resistance of bacteria, the lack of novel
and effective alternative drugs and the banning of anti-
microbials as growth promoters in some countries
emphasize the urgent need to develop and implement
alternative antimicrobials in Veterinary Medicine
(Aarestrup et al., 1998).
Bacteriophage and their derivatives are being consid-
ered valuable alternative antimicrobial solutions.
Bacteriophages (phages) are viruses that specifically
infect bacteria, being harmless to humans, animals and
plants. Their initial discovery in 1917 by d’Herelle led to
promising studies regarding their antimicrobial effi-
ciency, but they were stalled in the United States and
Western Europe by the development of antibiotics.
Nevertheless, research on phages and their medical
applications continued particularly in the former Soviet
Union and Eastern Europe (Sulakvelidze et al., 2001).
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More recently, with the emergence of multiple anti-
biotic-resistant bacteria, the interest in phage therapy
was renewed (Goodridge & Bisha, 2011, O'Flaherty
et al., 2009). Besides using the whole phage particle,
it is also possible to use their heterologous
expressed proteins with antimicrobial interest (as
lysins and depolymerases) (Oliveira et al., 2013;
Schmelcher et al., 2012a; Young, 2013, 2014).
Furthermore, the possibility of using simple method-
ologies for the genetic modification of phage
genomes offers several opportunities to improve
their antimicrobial and safety properties, as well as
for their prophylactic use as efficient antigen delivery
vehicles (phage vaccines) against viruses.
The phage-based solutions applied to animals or ani-
mal models described herein aim to highlight the exist-
ence of safe and efficient tools to treat and control
infections that cause diseases in food-producing ani-
mals. These may decrease the need for antibiotics with-
out impairing productivity, while simultaneously
offering environmental protection, by reducing the use
of agro-chemicals.
The main agents affecting food-producing
animals
There are hundreds of bacteria and viruses causing dis-
eases in food-producing animals, affecting one or more
animal species, with the most relevant presented in
Table 1.
Bacteria cause a diversity of diseases that vary with
the animal species, the agent gateway, the immune
response of the animal and the farm sanitation.
Likewise, viruses infect specific animals and have out-
comes that range from no symptoms to mild and life-
threatening diseases. These infectious diseases
adversely affect the profitability of farms, either by
animal death, fertility decrease and reduction of animal-
derived products such as milk, eggs or wool, or by caus-
ing low food conversion rates resulting in an increase of
food input for the same economic output (Lamy et al.,
2012). Furthermore, bacterial and viral diseases in ani-
mals have potentially serious impacts on human health.
In fact, more than 70% of all emerging human patho-
gens over the last years have been derived from patho-
gens originated from animals or products of animal
origin (zoonotic) (Jones et al., 2008; Woolhouse et al.,
2005). The World Health Organization (WHO, 2015) has
estimated that globally 2.2 million people die each year
from foodborne and waterborne diarrhoeal diseases
alone.
Approximately, 80 types of bacteria cause disease in
poultry industry, such as salmonellosis, pasteurellosis,
Table 1. Bacterial genera and virus families that cause disease
in food-producing animals (Bradley et al., 2015; FAO, 2015;
Merck, 2015; Persson & Bojesen 2015; VetBac, 2015).
Cattle Poultry Pigs
Small
ruminants
Bacterial genera
Actinobacillus
Actinomyces
Anaplasma
Avibacterium
Bacillus
Bibersteinia
Bordetella
Borrelia
Brachyspira
Brucella
Campylobacter
Chlamydia
Chlamydophila
Clostridium
Corynebacterium
Coxiella
Dermatophilus
Dichelobacter
Ehrlichia
Enterococcus
Erysipelothrix
Escherichia
Francisella
Fusobacterium
Gallibacterium
Haemophilus
Histophilus
Klebsiella
Lawsonia
Leptospira
Listeria
Mannheimia
Moraxella
Mycobacterium
Mycoplasma
Neorickettsia
Nocardia
Pasteurella
Peptoniphilus
Prevotella
Proteus
Pseudomonas
Rhodococcus
Salmonella
Serratia
Staphylococcus
Streptobacillus
Streptococcus
Treponema
Trueperella
Ureaplasma
Yersinia
Virus families
Adenoviridae
Arteriviridae
Asfariviridae
Astroviridae
Birnaviridae
Bornaviridae
Bunyaviridae
Caliciviridae
Circoviridae
Coronaviridae
Flaviviridae
Herpesviridae
Orthomyxoviridae
Papillomaviridae
Paramyxoviridae
Parvoviridae
Picomaviridae
Poxviridae
Reoviridae
Retroviridae
Rhabdoviridae
Togaviridae
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tuberculosis, staphylococcosis, streptococcosis, infec-
tious coryza, necrotic enteritis, avian chlamydiosis,
colibacillosis and mycoplasmosis (Hao et al., 2014;
Lima et al., 2016; Masdooq et al., 2008; Merck,
2015).
In cattle, mastitis (caused e.g. by Staphylococcus spp.
or Streptococcus spp.) is an important cause of eco-
nomic loss due to milk waste, treatment costs and pre-
mature culling of animals in severe cases (Heikkil€a et al.,
2012), while respiratory infections (caused e.g. by
Pasteurella spp., Mannheimia spp., Mycoplasma spp. or
Pseudomonas spp.) are associated to significant morbid-
ity and mortality (Royster & Wagner, 2015; Vogel et al.,
2001).
In pigs, respiratory diseases are the most important
health concern for swine producers nowadays, and are
often the result of a combination of primary and oppor-
tunistic infectious agents (Brockmeier et al., 2002).
Common respiratory diseases where bacteria are
responsible for significant economic losses are
Mycoplasma pneumonia and pleuropneumonia or
Haemophilus parasuis infections. Pasteurella multocida
and Bordetella bronchiseptica induce atrophic rhinitis
that is also an important predisposing factor for
increased respiratory diseases (Brockmeier et al., 2002;
Magyar & Lax, 2002; Merck, 2015; Nedbalcova et al.,
2006).
Viruses can also cause several diseases with further
complications. In fact, the host’s response to the viral
infection compromises its defense mechanisms, open-
ing the way to secondary bacterial infections (Folkerts
et al., 1990; Hodgins et al., 2002). Some examples are:
Parainfluenza-3 virus (Paramyxoviridae) induced pneu-
monia, Rotavirus (Reoviridae) and Coronavirus
(Coronaviridae) induced neonatal diarrhea, bovine
respiratory syncytial viral pneumonia, infectious bovine
rhinotracheitis, ovine progressive pneumonia, conta-
gious ecthyma in sheep and goats, infectious bronchitis
in poultry and Avian Gumboro disease caused by
the infectious bursal disease virus (Birnaviridae)
(Chakraborty et al., 2014; Guy, 1998; Kapil & Basaraba,
1997; Merck, 2015; M€uller et al., 2003; Saif, 2010; Torres-
Medina et al., 1985).
Phages and their derivatives as alternative
antimicrobials
Phages and phage proteins namely endolysins, exoly-
sins and depolymerases can present several advantages
as antimicrobials against bacterial infections that affect
food-producing animals. Despite tested in vitro, these
potential applications have also been tested in vivo
(Table 2) with some promising results.
Bacteriophages
Phages are the most abundant entities in the biosphere,
and can be isolated from several sources, including ali-
mentary tract of humans and animals, food, soil, water,
sewage and other environment niches. In fact, phages
can be found in the same environments where their
bacterial hosts exist (Bergh et al., 1989; Clokie et al.,
2011).
Most phages are very specific, normally infecting sin-
gle bacterial species or serovar groups, due to their
attachment to specific receptors on bacterial surface
before injecting their genetic material (Figure 1).
Virulent phages follow a lytic cycle, multiplying inside
the bacteria and lysing the cell to release new viruses.
In contrast, temperate phages follow a lysogenic life
cycle, integrating the bacterial genome without causing
cell lysis, but still being able to switch to a lytic cycle
under certain stimuli. For therapeutic or prophylactic
applications, non-transducing virulent phages should
be used to avoid the risk of virulence gene transduction
and to take advantage of their replication capacity (Gill
& Hyman, 2010; Kutter et al., 2010; Kutter &
Sulakvelidze, 2005).
Phages have many advantages over antibiotics for
therapeutic purposes, including: high specificity that
reduces damage caused to the normal host microbiota;
replication only at the site of infection; self-limiting and
self-dosing capacity i.e. replication only when sensitive
bacteria are present; and lower propensity to induce
resistance, especially when using a phage cocktail (Loc-
Carrillo & Abedon, 2011; €Orm€al€a & Jalasvuori, 2013;
Sulakvelidze et al., 2001).
Several in vivo studies support the use of phages as
an intervention strategy for reducing bacterial infec-
tions in food-producing animals.
In poultry, promising results were obtained for phage
therapy against Salmonella enterica serotypes
Typhimurium and Enteritidis, which may cause disease
especially in young chicks (Lima et al., 2016). The
importance of using phage cocktails and administering
high and multiple doses of phages was also demon-
strated (Berchieri et al., 1991; Fiorentin et al., 2005; Sklar
& Joerger, 2001). Phages given both by coarse spray
and in drinking water reduced Salmonella Enteritidis
intestinal colonization of broiler chicks, showing that
these means of phage administration are conceivable
and can ease the application and establishment of
phage biocontrol in an industrial environment (Borie
et al., 2008). The combined treatment with phages and
competitive exclusion products was also tested in birds,
against Salmonella infections, showing synergistic
effects (Borie et al., 2009). Other authors found that
CRITICAL REVIEWS IN MICROBIOLOGY 585
Table 2. Summary of in vivo studies evaluating bacteriophage and their derivatives against bacteria infecting food-producing
animals.
Treatment
agent
Animal
model Pathogen Delivery method Output Refs
Bacteriophages Poultry S. Enteritidis Oral gavage, cloacal Reduction in bacterial loads in cecal tonsils
24 h after treatment
Andreatti Filho et al.
(2007)
Aerosol spray,
drinking water
Reduction of intestinal colonization by both
delivery methods
Borie et al. (2008)
Aerosol spray Reduction of 3 log CFU in cecal contents
when phages were combined with com-
petitive exclusion products
Borie et al. (2009)
Oral Reduction of 3.5 log CFU on cecal contents Fiorentin et al. (2005)
Feed Prevention of horizontal bacterial transmis-
sion in the flock
Lim et al. (2012)
Oral, feed,
drinking water
Reduction of 0.3–1.3 log CFU in cecal
contents
Sklar & Joerger (2001)
S. Typhimurium Oral, feed High concentrations of phages reduced mor-
tality of birds
Berchieri et al. (1991)
Oral Reduction of Salmonella counts in cecum
and ileum; no clear synergism with com-
petitive exclusion products
Toro et al. (2005)
E. coli (APEC) Intramuscular Effective prevention and treatment of septi-
cemia and meningitis
Barrow et al. (1998)
Aerosol spray,
intramuscular
Reduction of bird mortality using intramuscu-
lar injection
Huff et al. (2003)
Intramuscular Total protection of birds using phage com-
bined with enrofloxacin
Huff et al. (2004)
Aerosol, drinking water Reduction of bird mortality using aerosol
administration
Huff et al. (2002)
Drinking water, spray Mortality reduced to levels below 0.5% in
naturally infected flocks
Oliveira et al. (2010)
Swine S. Typhimurium Oral Absence of clear evidences of intestinal
decrease of bacteria
Albino et al. (2014)
Oral gavage Reduction of >1.4 log CFU in cecal contents Callaway et al. (2010)
Oral, intramuscular Reduction of bacterial loads in pig tonsils (4
log CFU) and cecum (2 log CFU)
Lee & Harris (2001)
Oral gavage, feed Direct feeding of microencapsulated phages
led to a reduction of bacterial loads
Saez et al. (2011)
Oral gavage Microencapsulated phages led to a reduction
of bacterial counts (1–3 log CFU)
Wall et al. (2010)
E. coli (ETEC) Feed Reduction of 60% of bacterial loads in
challenged pigs
Cha et al. (2012)
Oral Reduction of the duration and severity of
diarrhea
Jamalludeen et al.
(2009)
Oral Efficient early treatment of ETEC diarrhea in
neonatal pigs
Smith & Huggins (1983)
Cows S. aureus Intramammary Non-statistically significant cure rate of
16.7%
Gill et al. (2006a)
Mice E. faecium Intraperitoneal Higher phage doses rescue 100% of mice
from bacteremia
Biswas et al. (2002)
Intraperitoneal Efficient rescue of infected mice using low
phage titer
Uchiyama et al. (2008)
P. aeruginosa Intraperitoneal Protection of mice against infection Soothill (1992)
Intraperitoneal 100% rescue of bacteremic mice Vinodkumar et al.
(2008)
Intraperitoneal Survival rate dependent on the time of
administration and phage dose
Wang et al. (2006)
K. pneumonia Intraperitoneal Effective treatment of infection only with
early phage administration
Chhibber et al. (2008)
Intraperitoneal,
intragastric
Inhibition of infection by phages at low
doses; intraperitoneal treatment more effi-
cient than intragastric
Hung et al. (2011)
Hamster C. difficile Oral Rescue most of the animals Ramesh et al. (1999)
Endolysins Mice S. pyogenes, MRSA Intraperitoneal Protection of 92% of mice from bacteremia Gilmer et al. (2013)
S. pyogenes Intraperitoneal Protection of mice from death (90–95%) in a
bacteremia model
Lood et al. (2014)
Oral, nasal Elimination of the pathogen in colonized
mice
Nelson et al. (2001)
S. agalactiae Intraperitoneal Protection of 80% of mice from infection Oechslin et al. (2013)
S. agalactiae,
S. dysgalactiae,
S. uberis
Intramammary Reduction of intramammary bacterial loads
(1.5–4.5 log)
Schmelcher et al.
(2015a)
S. pneumoniae Aerosol Reduction in mice mortality of 80% Doehn et al. (2013)
Intraperitoneal Rescue of mice from death due to endolysins
synergism
Jado et al. (2003)
(continued)
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although the combined treatment reduced the bacterial
colonization, this reduction was at least as effective as
phage treatment alone (Andreatti Filho et al., 2007;
Toro et al., 2005). Phages were also effective as a
prophylactic treatment for Salmonella Enteritidis. Lim
et al. (2012) revealed that phages prepared as feed
additives significantly prevented horizontal transmission
of bacteria from infected to healthy chicks within the
same flock, also reducing the environmental contamin-
ation level. In fact, 70% of the non-infected chickens
treated with phage had no detectable intestinal
Salmonella three weeks after treatment.
Regarding the control of the avian pathogenic
Escherichia coli (APEC), Barrow et al. (1998) showed that
phages were highly effective in both prevention and
treatment of experimentally induced septicemia and
meningitis. Huff et al. (2003) demonstrated that the effi-
cacy of phage treatment is dependent on the route of
administration, which in turn defines the phage titer
reaching the site of infection. Phages given as an aero-
sol spray or intramuscular injection immediately after
the E. coli challenge significantly reduced the mortality
of birds but when the treatment was delayed, only the
intramuscular injection was efficient. Also phages were
more effective when administered as multiple intramus-
cular injections rather than a single dose. Phages given
prophylactically as an aerosol significantly decreased
the mortality of birds while when added to the drinking
Table 2. Continued
Treatment
agent
Animal
model Pathogen Delivery method Output Refs
Intravenous, nasal, oral Reduction of bacterial loads in nasopharyn-
geal and bacteremia models; longer sur-
vival of animals
Loeffler et al. (2003)
Nasal, pharyngeal Reduction of bacterial loads to undetectable
levels
Loeffler et al. (2001)
Intraperitoneal Total protection of mice when administration
within 24 h; reduced protection in delayed
treatment (42% survival)
Witzenrath et al. (2009)
MRSA Intraperitoneal Protection of mice from bacteremia Gu et al. (2011)
Intravenous Increased survival rate and reduction of bac-
terial counts in the bloodstream
Jun et al. (2012)
Intraperitoneal, nasal Elimination of MRSA from the nares of mice
and protection against death
Rashel et al. (2007)
Intraperitoneal 100% protection from death; no clinical signs
of disease
Schmelcher et al.
(2015b)
B.anthracis Intraperitoneal Rescue of mice from fatal septicemia Schuch et al. (2002)
Rats S. pneumoniae Intravenous Elimination of pneumococci causing endocar-
ditis from blood within 30min with a
high-dose treatment
Entenza et al. (2005)
Rats, dogs MRSA Intravenous Absence of abnormal reactions to the
endolysin
Jun et al. (2014)
Engineered
endolysins
Mice MRSA Intraperitoneal Protection of mice from death with a syn-
ergy between the endolysin and oxacillin
Daniel et al. (2010)
Intraperitoneal 100% protection of mice from death Yang et al. (2014b)
S. aureus Topical Better performance (3 log CFU reduction)
than the antibiotic mupirocin
Pastagia et al. (2011)
Intramammary Reduction of 3.36 log CFU when combined
treatment with lysostaphin
Schmelcher et al.
(2012b)
S. pneumoniae Intraperitoneal 50% greater protection of mice compared to
the parental endolysin
Dıez-Martınez et al.
(2015)
Mice, rat S. aureus Intranasal,
intramammary,
intramuscular
Better activity than the parental protein in
models of nasal infection, mastitis and
osteomyelitis
Becker et al. (2016)
Zebrafish
embryos
S. pneumoniae,
S. pyogenes
Immersion Increased survival rate of 95-99%; combin-
ation with carvacrol was efficient in killing
Gram-negative bacteria
Dıez-Martınez et al.
(2013)
C. elegans P. aeruginosa Immersion Improved survival of nematodes with the
artilysin (63%) in relation to the native
endolysin (40%)
Briers et al. (2014a)
Exolysins Rat MRSA Intranasal Total decolonization of the nares of 44.4%
animals
Paul et al. (2011)
Depolymerases Poultry Salmonella Oral gavage Reduction of colonization and bacterial pene-
tration in internal organs
Waseh et al. (2010)
Rat E. coli Intraperitoneal Reduction of systemic infections and preven-
tion of death in at least 80% of infected
animals
Mushtaq et al. (2005)
Engineered phages Mice E. coli Intravenous Enhanced bacterial killing of phages when
combined with antibiotics
Lu & Collins (2009)
Intraperitoneal Reduced phage toxicity and immunogenicity
and improved survival of animals
Matsuda et al. (2005)
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water provided no protection (Huff et al., 2002). The
combination of the antibiotic enrofloxacin given in
drinking water and the intramuscularly administered
phage seemed to totally protect the challenged birds
(Huff et al., 2004). In a more recent study, Oliveira et al.
(2010) demonstrated the efficacy of a phage cocktail
given orally and by spray in controlling E. coli infection
in naturally infected flocks. The recorded mortality
before treatment ranged between 0.7 and 7.8%,
depending on the sampled flocks. After phage adminis-
tration, the mortality decreased to levels below 0.5%.
There are relatively few studies in which phages
have been used to control pathogens in swine. Smith &
Huggins (1983) performed the first study that demon-
strated the efficacy of phages given at the onset of diar-
rhea (13–16 h after infection) on the treatment of
experimental Enterotoxigenic E. coli (ETEC) diarrhea in
neonatal pigs. After the treatment, none of the pigs
died, diarrhea was mild and a 3-log reduction was
observed in fecal counts of ETEC. More recently,
Jamalludeen et al. (2009) showed that phages given
prophylactically or therapeutically to ETEC-infected
weaned pigs decreased the duration and severity of
diarrhea, without affecting the normal E. coli flora. Pigs
were pre-treated orally with sodium bicarbonate to pro-
tect the phages from the acidity of the stomach and
increase the numbers of viable phages entering the
intestinal tract. Also a virulent phage, administered in
feed one week before pigs were challenged with ETEC,
led to significantly reduced bacterial loads (Cha et al.,
2012).
Although a recent report on Salmonella control in
pigs by Albino et al. (2014) described the absence of
clear evidences in the intestinal decrease of Salmonella
Typhimurium after phage treatment, other studies
reported encouraging results, Lee & Harris (2001)
observed a significant reduction of Salmonella loads in
pig tonsils (4-log reduction) and cecum (2-log reduc-
tion) after phage administration; other authors showed
that administration of a phage cocktail given in feed or
by gavage to pigs challenged with Salmonella
Typhimurium, significantly reduced the bacterial load in
the feces (Callaway et al., 2010; Saez et al., 2011; Wall
et al., 2010).
Studies of phage efficacy to treat mastitis in lactating
cows have also been performed but were not conclu-
sive, requiring further experiments. For example,
although an intramammary infusion of phage given to
Figure 1. Schematic representation of the interactions between phages and phage-proteins (applied exogenously) and their
respective targeted structures on the cell wall of Gram-positive and Gram-negative bacteria. Illustration of phages as antigen
delivery vehicles against viruses and bacteria. CPS: capsular polysaccharides; LPS: lipopolysaccharides; PDV: phage display vaccine;
PDNV: phage DNA vaccine; HPV: hybrid phage vaccine.
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cows with pre-existing subclinical Staphylococcus aureus
infection led to a cure rate of 16.7%, the difference
between this and the non-treated group was not statis-
tically significant (Gill et al., 2006a). This can be due to
phage inactivation in the udder due to milk proteins
and fats since considerably lower rates of phages were
found in the milk for up to 36 h post-treatment.
Moreover, since S. aureus attaches to whey proteins and
aggregates in milk this can limit phage binding (Gill
et al., 2006b; O'Flaherty et al., 2005).
Other animal models have been used for phage ther-
apy experiments, in which phages were efficient in the
treatment of Enterococcus faecium (Biswas et al., 2002;
Uchiyama et al., 2008), Pseudomonas aeruginosa
(Soothill, 1992; Vinodkumar et al., 2008; Wang et al.,
2006), Clostridium difficile (Ramesh et al., 1999) and
Klebsiella pneumonia infections (Chhibber et al., 2008;
Hung et al., 2011).
Overall, despite several in vivo experiments demon-
strate that phages have potential as antimicrobials to
control infections in food-producing animals, they still
present limitations for therapeutic uses (Ly-Chatain,
2014). For example, although phages are less prone to
cause resistance than antibiotics, bacteriophage insensi-
tive mutants (BIMs) still occur, caused by the loss or
mutation of the bacterial receptor (Hyman & Abedon,
2010; Walmagh et al., 2012a), by the acquisition of
restriction–modification systems or by the development
of adaptive immunity through interfering clustered
regularly interspaced short palindromic repeats (CRISPR)
sequences (Hyman & Abedon, 2010; Labrie et al., 2010).
Other restrictions include the release of endotoxins
caused by rapid lysis of a large number of bacteria that
may cause allergic reactions (Drulis-Kawa et al., 2012;
Lawrence, 2010), the possibility of inducing an in vivo
anti-phage immune response, making it hard to sustain
an effective phage concentration (Lawrence, 2010), and
depending on the delivery system used, the achieve-
ment of an effective phage concentration at the site of
infection (Abedon & Thomas-Abedon, 2010).
In order to circumvent these limitations, several fac-
tors should be considered before phage application in
vivo. These include the appropriate selection of phages;
the use of phage cocktails with phages targeting differ-
ent surface receptors of the same target pathogen,
which can result in synergistic effects and reduction of
the likelihood of emergence of bacterial resistance; and
the optimization of the phage/bacteria ratio, timing and
route of phage delivery, according to the target patho-
gen and food-producing animal.
Apart from the biological limitations, regulatory
issues are still the major obstacle to phage therapy. The
uniqueness of phages as protein-based, live-biological
agents (Loc-Carrillo & Abedon, 2011), offer a challenge
to the regulatory agencies, which are struggling to find
the best approach to regulate phage products (Keen,
2012). Although phages have been suggested as a
“biological medicinal product” (Directive, 2001), requir-
ing clinical trials for each phage strain, or as an
“advanced therapy medicinal product” (Directive, 2003;
Verbeken et al., 2007), with regulation based on manu-
facturing processes without mandatory clinical trials
(Directive, 2003), no final decision has been taken so far.
Phage-encoded proteins
Recently, phage proteins, as endolysins, exolysins and
depolymerases (Figure 1) have been explored as anti-
microbial therapies, either alone or in combination with
other agents.
Although some authors consider endolysins and
exolysins in the category of depolymerases, we will
exclude them from this class and mention each one
separately.
Endolysins
Endolysins are enzymes produced by phages at the end
of their replication cycle to digest the bacterial cell wall
peptidoglycan (PG), allowing the release of phage pro-
geny. Most endolysins show a modular organization,
comprising a catalytic domain (CD) and a cell wall-bind-
ing domain (CBD). The CBD binds to the PG or another
cell wall component, allowing the CD to cleave a spe-
cific bond in the PG structure. Based on their catalytic
activity site on the PG, endolysins can be muramidases,
glucosaminidases, transglycosylases, amidases or endo-
peptidases (Schmelcher et al., 2012a).
These enzymes present several advantages as antimi-
crobials: they are, in general, very specific to the patho-
gen and thus do not disturb the normal microflora; so
far, no resistance mechanisms or resistant phenotypes
were detected after endolysins exposure, probably
because these enzymes target essential structural com-
ponents for bacterial viability and since they are applied
exogenously they act on the outside of the cell, thereby
avoiding a majority of possible resistance mechanisms
(Fischetti, 2005; Loeffler et al., 2001, 2003; Nelson et al.,
2001; Schmelcher et al., 2012a; Schuch et al., 2002); no
signs of toxicity have been noticed after endolysins’
treatment of systemic infections in mouse models (Jado
et al., 2003; Loeffler et al., 2003; McCullers et al., 2007;
Nelson et al., 2001); and the immune response induced
by endolysins apparently does not neutralize their activ-
ity or prevent their use to treat systemic infections
(Fischetti, 2005; Loeffler et al., 2003).
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Most of the work described with endolysins concerns
Gram-positive bacteria, because Gram-negative bacteria
have a highly impermeable outer membrane (OM) that
limits the access of endolysins to the PG, when applied
exogenously. Therefore, in order to lyse Gram-negative
bacteria, most endolysins require physical treatment or
chemical OM disruption agents, namely polycationic
agents and chelators (Briers et al., 2008a, 2011;
Walmagh et al., 2012b). Another option is to genetically
engineer endolysins, as exemplified by the Artilysins
(detailed below). Nevertheless, some endolysins have
been reported to cross the OM and kill Gram-negative
bacteria without chemical or physical treatment.
Examples include the Salmonella phage endolysin
SPN9CC (Lim et al., 2014), the Bacillus amyloliquefaciens
phage endolysin Lys1521 (Morita et al., 2001a; Orito
et al., 2004) and the Acinetobacter baumannii phage
endolysin LysAB2 (Lai et al., 2011). Most of these
enzymes have amphipathic or highly cationic regions
that interact with the LPS to cross the OM (Lai et al.,
2011; Morita et al., 2001b; Walmagh et al., 2012a).
Some phage endolysins have demonstrated capacity
to kill some of the most prevalent Gram-positive patho-
gens such as S. aureus and Streptococcus uberis which
cause mastitis in cows (Celia et al., 2008; Donovan et al.,
2006; Horgan et al., 2009; Obeso et al., 2008) and
Streptococcus suis which cause endocarditis and septi-
cemia in pigs (Wang et al., 2009).
In animal models, endolysins have shown efficacy in
the treatment and protection against a wide range of
Gram-positive pathogens that infect animals and
humans.
For Streptococcus pyogenes, oral administration of
endolysin PlyC to colonized mice eliminated the patho-
gen within 2 h (Nelson et al., 2001). Also an intraperito-
neal injection of the endolysin PlyPy (Lood et al., 2014)
or PlySs2 (Gilmer et al., 2013) protected mice from
death in a bacteremia model of S. pyogenes infection or
a combined MRSA (Methicillin-resistant S. aureus) and S.
pyogenes infection. For Streptococcus agalactiae,
repeated intraperitoneal injections of PlySK1249 signifi-
cantly protected mice from the infection (Oechslin
et al., 2013). In a mouse model of bovine mastitis, intra-
mammary infusions of endolysins kSA2 and B30 led to
a significantly reduction on the intramammary concen-
trations of the S. agalactiae, Streptococcus dysgalactiae
and Streptococcus uberis (except for B30 vs. S. dysgalac-
tiae) (Schmelcher et al., 2015a).
On Streptococcus pneumoniae, endolysins showed
potential to control and treat mucosal and systemic
infections. Several methods of delivering endolysin CpI-
1 to infected mouse models were tested with different
outcomes. When Cpl-1 was given intravenously, the
bacterial loads were reduced to undetected levels
within 15min. Nevertheless, the treated animals died
from the infection, possibly due to the relatively short
half-life of Cpl-1 in the blood (15–20min), which indi-
cates that additional doses of Cpl-1 could be needed to
completely eradicate S. pneumoniae (Loeffler et al.,
2003). Endolysins Cpl-1 and Pal applied intraperitoneally
to S. pneumoniae infected mice, acted synergistically
and rescued mice from death (Jado et al., 2003). Also
Witzenrath et al. (2009) showed that when applying
endolysin Cpl-1 24 h after bacterial challenge with S.
pneumoniae, mice were fully protected. However, when
treatment was delayed for 2 days, the survival rate
reduced to 42%. CpI-1 was also given by aerosol to
infected mice after the onset of pneumonia and
reduced the mortality by 80% (Doehn et al., 2013). Cpl-
1 was also efficient in the elimination and prevention of
acquired S. pneumoniae endocarditis in rats (Entenza
et al., 2005). The application of the endolysins Pal or
Cpl-1 has successfully eliminated S. pneumoniae from
the nares of mice (Loeffler et al., 2001, 2003).
Phage endolysins have also been shown to be
powerful therapeutic agents against multidrug-resistant
S. aureus infections and protected mice from death
when administered intraperitoneally (Gu et al., 2011;
Rashel et al., 2007; Schmelcher et al., 2015b). An endoly-
sin-based pre-formulation (SAL200), administered as an
intravenous injection in a mouse model of MRSA infec-
tion, reduced Staphylococcus counts in the bloodstream
and prolonged survival of mice (Jun et al., 2012).
In a preclinical study with rats and dogs, repeated intra-
venous treatment with SAL200 did not induce signs of
toxicity (Jun et al., 2014). Regarding Bacillus anthracis,
endolysin PlyG, applied as an intraperitoneal injection,
rescued mice from fatal septicemia (Schuch et al., 2002).
Phage endolysins have also shown to act synergistic-
ally with other endolysins (Jado et al., 2003; Loeffler &
Fischetti, 2003), bacteriolytic enzymes such as lysosta-
phin (Becker et al., 2008; Schmelcher et al., 2012b) and
antibiotics (Daniel et al., 2010; Djurkovic et al., 2005;
Rodrıguez-Cerrato et al., 2007).
Holins are proteins encoded by phages during the
late phase of the lytic cycle and are involved in the per-
meabilization of the membrane, allowing endolysins to
cross into the periplasm and degrade the PG (Wang
et al., 2000). The combined use of holins and endolysins
might be a promising strategy for antimicrobial therapy.
Shi et al. (2012) combined the holin HolSMP and the
endolysin LySMP, resulting in an extended spectrum of
the endolysin against strains of multidrug-resistant S.
suis and S. aureus.
Due to their modular structure, endolysins can be
genetically engineered to display desired functional
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properties such as extended host spectra, improved
lytic activity, solubility and ability to infect Gram-nega-
tive bacteria (Fernandes et al., 2012; Yang et al., 2014a).
The modular engineering of endolysins involves the
shuffling of natural lysins domains, generating chimeric
lysins (or “chimeolysins”), or the fusion of a natural lysin
or part of its domain with another component from a
peptide or a protein (artificial lysins or “artilysins”).
Recent studies demonstrated that chimeolysins have
increased lytic activity and a host range broader than
natural enzymes (Becker et al., 2009; Dong et al., 2015;
Mao et al., 2013; Schmelcher et al., 2011).
In vivo studies proved the efficacy of treatment with
genetically modified endolysins in animal models
against human and animal infections.
The chimeolysins ClyH and ClyS when given as an
intraperitoneal injection, protected mice from death by
MRSA (Daniel et al., 2010; Yang et al., 2014b). The chi-
meolysin ClyS, when applied topically, performed better
than the antibiotic muciporin in a mouse model of skin
colonization/infection with S. aureus (Pastagia et al.,
2011). An engineered triple-acting staphylolytic endoly-
sin reduced colonization by S. aureus in a rat nasal col-
onization model, surpassing the efficacy of either
parental protein. When this protein was modified with a
transduction domain and tested in a mouse model of
mastitis, it demonstrated significantly improvement on
the ability to kill intracellular S. aureus (Becker et al.,
2016). Also, an intramammary infusion of the chimeric
endolysins kSA2-E-Lyso-SH3b or kSA2-E-LysK-SH3b
reduced S. aureus loads by 0.63 or 0.81 log units in a
mouse model of mastites. When kSA2-E-LysK-SH3b was
administered in combination with lysostaphin, a 3.36
log reduction was observed in the Staphylococcus loads
(Schmelcher et al., 2012b).
A single dose of chimeolysin Cpl-7S significantly
increased the survival rate of infected zebrafish embryos
for S. pneumoniae and S. pyogenes (Dıez-Martınez et al.,
2013). Similarly, a single intraperitoneal injection of the
chimeric protein Cpl-711, administrated 1 h after S.
pneumoniae challenge, resulted in about 50% greater
protection of mice than with the parental endolysin
(Dıez-Martınez et al., 2015).
As stated above, the major drawback of endolysins is
their limited action against Gram-negative bacteria. This
was overcome by engineering these enzymes as outer
membrane-penetrating endolysins (Artilysins). Briers
et al. (2014a) fused endolysins with different LPS-desta-
bilizing peptides with polycationic, hydrophobic and
amphipathic properties, enabling the enzymes to pass
the OM and become active against Gram-negative bac-
teria. For example, the artilysin LoGT-001 was able to
kill P. aeruginosa (5.50-log), A. baumannii (5.18-log), E.
coli (2.41-log) and S. Typhimurium (1.52-log) cells in
30min. LoGT-001 was tested in vivo in a Caenorhabditis
elegans infection model with P. aeruginosa leading to a
survival of 63 ± 4% nematodes 5 days postinfection,
while 90% of the animals that did not receive the
Artilysin were killed. Recently, the construction of artily-
sins by fusing endolysins with antimicrobial peptides
(AMPs) which have a self-promoted uptake mechanism
across the OM was reported. Artilysins Art-085 and Art-
175, which result from the fusion of an AMP sheep mye-
loid 29-amino acid (SMAP-29) peptide with the KZ144
endolysin, were able to cross the OM and reduce P.
aeruginosa loads by 5-log in vitro (Briers et al., 2014b).
In two case studies of dogs with otitis, the treatment
with Art-085 was able to cure the animals from an infec-
tion by P. aeruginosa, which was not eliminated with
standard antibiotics (Briers & Lavigne, 2015).
Exolysins or VAPGHs (virion-associated peptidogly-
can hydrolases)
Exolysins are another type of peptidoglycan enzymes
encoded by some phages that, in contrast to endoly-
sins, are present as part of the phage structure and par-
ticipate in the first step of phage infection. VAPGHs
degrade the peptidoglycan, enabling phages to reach
the bacterial cytoplasmic membrane thus facilitating
DNA injection into the host cell (Letellier et al., 1999).
These proteins have been identified in phages infecting
both Gram-positive and Gram-negative bacteria
(Moak & Molineux, 2004). Few VAPGHs have so far been
analyzed, however, some studies show their antimicro-
bial activity when applied exogenously (Rashel et al.,
2008; Rodrıguez et al., 2011; Takac & Bl€asi, 2005).
Like endolysins, VAPGHs have limited activity against
Gram-negative bacteria due to the presence of an OM.
However, some VAPGH have shown activity in vitro
against Gram-negative bacteria when used with OM
destabilizing conditions (Briers et al., 2008b; Caldentey
& Bamford, 1992; Lavigne et al., 2004).
VAPGHs present several advantages as antimicro-
bials: high thermostability and specificity (Lavigne et al.,
2004), a low probability of bacterial resistance, and a
modular organization that allows the construction of
chimeric proteins with multiple domains to improve
their antimicrobial activity.
Rodrıguez-Rubio et al. (2012) discovered that trun-
cated derivatives and fusion proteins of HydH5, a
VAPGH from a S. aureus phage, exhibited high lytic
activity against S. aureus when compared with the par-
ental enzyme and displayed antimicrobial synergy with
the endolysin LysH5. These proteins are promising
agents against S. aureus, which cause bovine mastitis,
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since they were able to prevent its growth in milk
(Rodrıguez-Rubio et al., 2013). The chimeric protein
P16–17, composed of the N-terminal endopeptidase
domain of endolysin Lys16 and the C-terminal CBD of
VAPGH P17, exhibited antimicrobial activity towards S.
aureus and augmented the antimicrobial efficacy of the
antibiotic gentamicin (Manoharadas et al., 2009).
Similarly, the chimeric exolysin P128, composed by a
tail-associated muralytic enzyme (TAME) from phage K
and a lysostaphin SH3 cell wall-targeting domain,
showed a potent anti-staphylococcal activity in vitro.
Moreover, when tested in a mouse infection model,
P128 reduced MRSA colonization of rat nares by 2-log
(Paul et al., 2011).
Depolymerases
Depolymerases are phage-encoded proteins that have
glycanase-like activity and digest the polysaccharides of
the bacterial cell wall, namely lipopolysaccharides (LPS)
and capsular polysaccharides (CPS).
Although some of these proteins are soluble and
generated during host cell lysis, the majority of the
described phage depolymerases are structural proteins,
facilitating phage infection (Oliveira et al., 2013).
According to their mode of action, phage depoly-
merases can be hydrolases if they catalyze the hydroly-
sis of glycosidic bonds, or lyases if they cleave (1,4)
glycosidic bonds by a b-elimination mechanism
(Oliveira et al., 2013).
There are still few in vivo studies in which depoly-
merases were applied. Mushtaq et al. (2005) showed
that a depolymerase with endosialidase activity (endoE)
administered to rats reduced systemic E. coli infections,
suggesting that the degradation of the bacterial CPS
decreased its virulence and sensitized cells to host
defenses. Waseh et al. (2010) also demonstrated that
the oral administration of a tail spike protein with endo-
rhamnosidase activity reduced Salmonella colonization
in chickens. This may be attributed to the binding of
the protein to the O-antigen hence compromising the
structure of LPS and, consequently, reducing bacterial
motility and infectivity.
Phage-derived vaccines
Although the importance of innovation on therapeutic
approaches is irrefutable, preventing diseases is
always preferable to treatment. Vaccines are one of
the most important immunomodulators, acting by
stimulation of the body's immune system to recog-
nize the agent as foreign, enabling infection control.
Therefore, the use of vaccines may decrease the need
for antibiotics, contributing to improve health, welfare
and production yields in animal husbandry (Prisco &
De Berardinis, 2012).
Conventionally, a vaccine contains the causative
agent of the disease, genetically engineered microbes,
vectored antigen formulations or naked DNA (DNA
vaccines).
Recently, phages are also considered as vaccine-
delivery vehicles against bacterial or viral infections, as
they possess numerous intrinsic characteristics making
them promising tools in this field. Presently, two distinct
approaches are proposed, either used independently or
combined: phage display vaccines and phage DNA vac-
cines (Clark & March, 2004a) (Figure 1).
In phage display vaccines, specific proteins or pepti-
des from the antigens of interest are engineered to be
expressed on the phage surface, leading to an immuno-
genic response (Clark & March, 2006). The conception of
these vaccines relies on the phage display technology,
which allows the fusion of the DNA coding a polypep-
tide with phage structural protein genes, enabling the
expression of the former protein on the phage surface
(Sidhu, 2000; Smith, 1985). Some phages were already
identified as advantageous for this purpose, as T4, T7,
lambda phages and the filamentous M13. The T4 phage
allows the display of large peptides on its capsid pro-
teins, Soc (small outer capsid protein; 960 copies per
particle) and Hoc (highly antigenic outer capsid protein;
160 copies per particle) (Li et al., 2006). In the T7 phage,
the fusion proteins are displayed on protein 10B (5–15
copies) of the major phage capsid (gp10), and in the
lambda phage both the tail protein gpV (at least 5 cop-
ies) and the head protein gpD (405–420 copies) have
been used for displaying foreign peptides (Sundell &
Ivarsson, 2014). The M13 phage is a highly versatile sys-
tem as distinct coat proteins can be used for peptide
display. Commonly, the pIII protein is used for low
valency display (1–5 copies per phage) and the pVIII for
high valency display (up to 1000 copies per phage)
(Sundell & Ivarsson, 2014).
In phage DNA vaccines, phages are used as vehicles
for the delivery of the foreign antigen DNA incorpo-
rated into the phage genome, under the control of
strong eukaryotic promoters. Lambda phage vectors are
commonly used for this purpose (Clark & March, 2004a).
Inside the animal organism, the antigen gene will be
expressed in targeted cells from the immune system
(Clark & March, 2006), originating an immune response.
Overall, vaccines lead to humoral (antibody-depend-
ent) and/or cellular (cell-dependent) immune responses
through the combined role of different groups of cells:
antigen-presenting cells (APC), which capture and
display antigens to another group, the regulatory T-
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lymphocytes (Helper cells – HC), which when activated
induce the activity of the effector cells (EC) that will
accomplish the elimination of antigens (Siegrist, 2012).
The humoral response is mediated by B-lymphocytes
(APC), and might be triggered by immunogenic anti-
gens, as the peptides displayed in the surface of phage
display vaccines. After the intervention of HC and EC,
antibodies will be released, and memory B-cells will
remain for subsequent exposures. In the cellular
immune response and in the case of a DNA phage vac-
cine, macrophages or dendritic cells (APC) will translate
the foreign antigen DNA into peptides, inducing
through HC the activation of phagocytic cells and cyto-
toxic T-lymphocytes (remain as memory cells) that will
destroy the antigen (Figure 2).
Recent studies reported the possibility of producing
a hybrid phage vaccine, combining the two versions of
phage vaccines. Here, the DNA vaccine is enclosed
within the phage particle and a phage-display variant of
the same antigen is present on the phage surface, with
specific binding affinity to the APC (Clark & March,
2006). This combination has the advantage of delivering
the antigen gene directly to the immunoreactive cells,
efficiently targeting both humoral and cellular immune
systems (Clark & March, 2006; Haq et al., 2012; Zanghi
et al., 2007) and, consequently, enhance the vaccine
specificity and the effectiveness of the immune
response.
In broad terms, phage vaccines have several advan-
tages relatively to the conventional ones (Clark &
March, 2004a; Olofsson et al., 2008). Phage vaccines can
be economically manufactured, due to the possibility of
rapidly obtaining high phage titers on relatively inex-
pensive media, with straightforward purification steps.
These features allow the attainment of sufficient quanti-
ties of vaccines against new pathogens as, for example,
during disease outbreaks. Moreover, the lack of patho-
genicity of the phage particles in animals and their
increased chemical stability are also important when
safety issues are concerned. Also, phages enclose nat-
ural adjuvant properties that confer them a real advan-
tage in relation to conventional vaccines. Adjuvants are
Figure 2. Schematic example of the innate and adaptive (humoral and cellular) immune system response activated by different
types of phage vaccines: phage display vaccines, phage DNA vaccines and hybrid phage vaccines. APC: antigen presenting cells;
EC: effector cells; HC: helping cells.
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compounds that enhance the specific immune response
against co-inoculated antigens, particularly by stimulat-
ing antibodies production. This feature is related to the
presence of unmethylated CpG dinucleotides (cytosine-
phosphodiester linked-guanine), naturally found in the
phage genome and able to be recognized by the innate
immune cells through protein receptors (Toll-like recep-
tors) (Adhya et al., 2014; Krieg et al., 1995; Mason et al.,
2005).
Particularly for phage DNA vaccines, apart from the
already mentioned manufacturing advantages, the pos-
sibility of ensuring the absence of antibiotic resistance
genes, the large cloning capacity of the phage vector
(e.g. 15–20 kb can be used in standard lambda vector),
the potential for oral delivery, and the natural protection
offered by the phage capsid to DNA against environ-
mental degradation (contrarily to naked DNA vaccines)
are some other relevant advantages (Clark & March,
2004a). Additionally, enclosure of foreign DNA in a
phage that acts as a particulate antigen, enables both
the induction of antibody production (humoral
response) and the activation of the cellular immune
response (Gaubin et al., 2003), enhancing the vaccine
efficacy.
However, there are still few studies in which phage
particles displaying antigenic proteins have been used
as vaccines in animal models (Bazan et al., 2012). An
example of an effective phage display vaccine was
reported by Hayes et al. (2010). In this work, immunodo-
minant regions of the porcine circovirus were success-
fully displayed in lambda phage capsid, and
neutralizing antibodies were produced against this
infection in pigs, stimulating both cellular and humoral
immune responses.
Wu et al. (2007) used the phage T4 HOC, SOC dual
site display system, hence leading to a simultaneous dis-
play of two different antigens on the T4 capsid surface.
The resultant phages were administered to mice as a
vaccine against classical swine fever virus (CSFV). The
results of animals’ immune response revealed that the
antibody titers elicited in mice by the T4 phage-CSFV
recombinants were significantly higher than those
obtained by immunization with recombinant antigens
produced by conventional expression in recombinant E.
coli cells. In another work, an orally delivered foot-and-
mouth disease virus (FMDV) vaccine, in which the capsid
protein was displayed on the surface of T4 phage par-
ticles, conferred mice 100% protection against a lethal
dose of a FMDV-O serotype. Moreover, pigs immunized
with this vaccine were protected when animals were
cohoused with FMDV-infected pigs (Ren et al., 2008).
Hashemi et al. (2012) concluded that the genetic
fusion of a domain of influenza A virus (M2 protein)
with T7 phage-based particles effectively protected
mice against this disease, even without adjuvant, as the
defense cells’ secretion frequency was comparable to
those elicited by the peptide itself, emulsified in the
conventional adjuvant.
Hashiguchi et al. (2010) described a strong IgG pri-
mary response in mice and the induction of long-lasting
antibody response with a single immunization with
M13 phage injected intraperitoneally, suggesting this
phage as a potential vaccine carrier.
Regarding phage DNA vaccines, there are few studies
designed for food-producing animals’ infections, and
most target humans’ pathogens (Clark & March, 2004a,
2004b). Ou et al. (2013) tested a lambda phage-medi-
ated DNA vaccine against Chlamydia abortus in piglets
and proved its capacity of inducing antigen-specific cel-
lular and humoral immune responses providing protect-
ive immunity.
Genetically-modified phages
Recent developments on genetic tools are creating new
opportunities for the modification of phage genomes to
improve their properties for therapeutic and prophylac-
tic applications (Nobrega et al., 2015; Pires et al., 2016).
These tools include bacteriophage recombineering of
electroporated DNA (BRED), yeast artificial chromosome
(YAC) and the CRISPR–Cas system.
BRED (Marinelli et al., 2008) uses bacterial overex-
pression of plasmid-encoded recombination genes (e.g.
the lambda Red system) to enhance the frequency of
homologous recombination between phage DNA and
DNA substrate after electroporation (Feher et al., 2012;
Marinelli et al., 2012). YAC (Lu et al., 2013) consists on
the insertion of the whole phage genome inside a YAC
vector by homologous recombination, creating a
recombinant YAC that is propagated in the vector host
where the phage genome can be modified by yeast
recombineering. The modified YAC may then be
inserted into bacteria for phage replication. The
CRISPR–Cas system is the most recent tool for the gen-
etic modification of phages. This system is involved in
the protection of microbial cells from DNA invasion and
comprises an array of repeats and spacers. Transcribed
spacers guide specific proteins to the target DNA (e.g.
phage DNA), and cleave it. The break can then be
repaired by homologous recombination if a mutated
template is provided (Kiro et al., 2014). Compared with
other methods, CRISPR–Cas provides higher percen-
tages of mutated phages, simplifying selection and
recovery (Kiro et al., 2014; Martel & Moineau, 2014).
There are several examples of the use of these
techniques for genetic manipulation of phage
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genomes with therapeutic interest. One of the main
goals is the extension of phage host range, which
has been achieved, for example, by designing phage
T7 for the expression of an endosialidase degradative
of the K1 capsule that is present in some E. coli
strains (Scholl et al., 2005) or by replacing the host
binding genes of phage T2 for those of phage PP01
(Yoichi et al., 2005). It is also important to reduce
phage toxicity and immunogenicity that may hinder
therapeutic efficacy and cause adverse side effects.
This can be achieved by developing lysis-deficient
and non-replicating phages, avoiding toxin release
during bacterial lysis in vivo (Hagens et al., 2004;
Matsuda et al., 2005). Some manipulations have been
performed to enhance phage survival after administra-
tion, including the introduction of a single specific
mutation on a phage genome that resulted in the
generation of long-circulating phages (Vitiello et al.,
2005). It is also possible to improve phage activity
against biofilms, as demonstrated by Lu & Collins
(2007) with the engineering of T7 for the expression
of dispersin B, a biofilm-degrading enzyme, which
resulted in a 100,000 fold increased efficiency. Genetic
modification has also been used to enhance bacterial
killing of phages when combined with antibiotics, for
example by engineering lysogenic phages to overex-
press proteins that target specific nonessential gene
networks (Lu & Collins, 2009).
Future perspectives
In an era of increasing emergence of multi-drug resist-
ant pathogens and a scarcity of new antimicrobials,
together with the restrictions imposed by European
Union to the use of traditional antibiotics in animal hus-
bandry, there is an urgent need to find antimicrobial
alternatives.
Phage-based solutions presented herein have poten-
tial as therapeutic or prophylactic tools for application
in livestock production. In fact, there is compelling
evidence from the in vitro and in vivo studies of the
potential of phages against an array of Gram-positive
and Gram-negative bacterial pathogens that infect
food-producing animals.
Phage particles pose several intrinsic characteristics
that make them profitable for the development of prod-
ucts to treat or prevent diseases, as well as for the
design of vaccine-delivery platforms. The natural stabil-
ity, easy production and purification of phages provides
cheaper and large-scale capacity for the manufacturing
of these products. However, the acceptance of phages
for this purpose will depend on its efficacy, safety and
cost compared with other interventions. Therefore, a
more detailed biologic and genetic characterization of
phages is mandatory to avoid undesirable outcomes.
These include a bacterial adaptive response to phage
infection by the generation of BIMs or even an increase
in bacterial virulence when phages transfer virulent
genes such as toxin and antibiotic-resistant genes
among bacteria. Moreover, the efficacy of phage ther-
apy requires an appropriate choice of phages, dosage,
delivery route and timing of administration, which
should be adapted according to the pathogen and ani-
mal targeted.
From another point of view, the development of
synthetic biology and molecular tools enables the
construction of genetically-modified phages with valu-
able features such as extension of the host range,
reduced toxicity and immunogenicity and enhanced
survival after administration. Moreover, it also allows
to use phage proteins, namely endolysins and exoly-
sins, that present broader antibacterial spectrum,
lower immunogenicity and low probability of bacterial
resistance and thus can be considered as potentially
valuable therapeutics to fight infections. Until now,
these enzymes target mainly Gram-positive bacteria
but further screening for new ones or engineering
these enzymes combined with other proteins, as OM
transporters or holins to target Gram-negative bac-
teria is ongoing, and it is expected to increase the
value of phage enzymes as therapeutics for both
human and animal health.
Despite all the reported evidences of success on
using phage-derived solutions presented herein, the
use of these antimicrobials to completely substitute
antibiotics is not a straightforward or probable
approach, mainly because antibiotics have several uses
in the animal production, such as prevention and treat-
ment of diseases and promotion of growth. Therefore,
the combination of phage-based alternatives with
the traditional ones, when used rationally, may be a
path to follow.
Another important issue regarding animal produc-
tion is the scarce number of studies directed for veterin-
ary purposes. The urgent requisite of decreasing
antibiotic use in food-production animals should
encourage researchers to design experiments specific-
ally for animal applications.
Furthermore, it is urgent that regulatory bodies
establish protocols for phage product regulation, so
that the use of phages in veterinary applications does
not remain stalled by regulatory issues. Regulatory
bodies such as the US Food and Drug Administration
(FDA), the US Department of Agriculture (USDA) and
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the European Medicines Agency (EMEA) have shown
some flexibility in approving the use of phages for con-
trol of several problematic pathogens.
Presently, there are already several companies devel-
oping phage products that can be used in Veterinary
Medicine. These comprise BioPhage-PA, a topical phage
product for chronic otitis against antibiotic-resistant P.
aeruginosa that has already completed the phase I/II of
clinical trials, and ViridaxTM, for the treatment of respira-
tory, systemic and topical infections of S. aureus and
other Staphylococcal species. Other products were
already approved and are being commercialized. These
include: feed additives, such as BioTector to control
Salmonella in poultry; products for direct food applica-
tions, such as ListShieldTM and Listex P-100TM for Listeria
monocytogenes, EcoShieldTM for E. coli O157:H7,
SalmonelexTM and SalmoFreshTM for Salmonella; and
products for agricultural use, such as AgriPhageTMM to
control Xanthomonas campestris or Pseudomonas syrin-
gae on crops. OmnilyticsTMM also has some approved
products that target Salmonella and E. coli O157:H7 on
cattle hides and poultry prior to slaughter.
Overall, the continuous research of the already exist-
ing antibiotic alternatives and the development of safe
and efficient new ones, is needed to combat the threat
of antibiotic resistant pathogens and to ensure sustain-
able animal and human welfare.
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